GoodRx Earnings Call Marks Transitional Reset Year

Goodrx Holdings, Inc. ((GDRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

GoodRx Holdings’ latest earnings call painted a transitional picture for investors, blending solid execution in growth initiatives with clear pressure in its legacy business. Management highlighted resilient 2025 results, accelerating Pharma Direct growth, and strong platform scale, but also acknowledged declining prescription volumes, weaker unit economics, and a 2026 outlook that bakes in lower revenue and EBITDA as the company invests for durability.

Stable 2025 Top Line and Margin Delivery

GoodRx closed 2025 with revenue of $796.9 million, up 1% year over year, and Adjusted EBITDA of $270.5 million, up 4%, landing in line with guidance and slightly above the midpoint on profitability. Fourth quarter revenue reached $194.8 million with $65 million in Adjusted EBITDA, underscoring the company’s ability to hold margins even as key parts of the legacy prescription transactions business softened.

Pharma Direct Emerges as Core Growth Engine

Pharma Direct, previously called Pharma Manufacturer Solutions, posted 41% year-over-year growth to $151.4 million in 2025 and is expected to grow at least 30% in 2026. Management positioned this segment as the centerpiece of GoodRx’s strategic pivot toward manufacturer-driven, direct-to-consumer pricing, framing it as both the primary growth driver and a hedge against structural pressure in traditional prescription discounts.

Leveraging Platform Scale and Consumer Reach

The company underscored its scale, citing nearly 300 million annual site visits, the top-ranked prescription app, about 25 million consumers, and over 1 million healthcare professionals engaging with the platform each year. This reach underpins GoodRx’s pitch to manufacturers and pharmacies, enabling broad distribution for new drug launches, savings programs, and brand campaigns across a large, targeted audience.

Wegovy Launch and Brand Programs Gain Traction

GoodRx estimated it handled nearly 20% of all Wegovy pill self-pay fills during a single week in January, highlighting the platform’s role in high-demand therapies. With roughly 200 manufacturer partnerships and more than 100 brand self-pay programs live, many integrated into TrumpRx and pharmacy partners, management argued that its infrastructure is increasingly embedded in branded drug access and affordability.

E-Commerce and Rx Marketplace Expansion Accelerates

In the fourth quarter, GoodRx tripled its retail footprint and ended the year with six of the top ten retail pharmacies live on its e-commerce platform, alongside direct contracts with nine of the top ten retailers. Order volume surged 83% quarter over quarter in Q4, reinforcing momentum in its online pharmacy marketplace and offering a potential new layer of growth beyond traditional coupon-based transactions.

Balance Sheet Strength and Share Buybacks Signal Confidence

The company exited 2025 with $261.8 million of cash on hand and roughly $80 million of undrawn capacity on its revolving credit facility, providing ample liquidity for investment. Management also repurchased approximately 48.9 million shares for $217.4 million at an average price of $4.45, signaling confidence in long-term value despite near-term earnings pressure.

Pressure on Prescription Transactions Revenue

Prescription transactions revenue fell 6% year over year to $544 million in 2025, and management expects continued pressure in 2026 as it prioritizes more durable economics over headline growth. The decline reflects strategic trade-offs, including pricing and contract changes, as well as volume headwinds that weigh on GoodRx’s traditional savings card and coupon business.

Subscriptions Show Promise but Remain Small

Subscription revenue slipped 3% year over year to $83.8 million in 2025, indicating that this stream is still in the early innings of monetization. Condition-specific offerings such as weight loss, erectile dysfunction, and hair loss subscriptions are showing encouraging early traction, and management expects them to become more meaningful contributors starting in 2026.

Monthly Active Consumers Trend Lower

Monthly active consumers declined 14% in 2025 versus the prior year, highlighting softer engagement and volume in GoodRx’s core marketplace. While the company expects MACs to level off and remain roughly flat from the fourth quarter of 2025 through the fourth quarter of 2026, the drop underscores a key risk to growth if newer products do not fully offset reduced activity in legacy channels.

Unit Economics Reset Weighs on Near-Term Revenue

GoodRx disclosed a major reset in unit economics, negotiating lower fees with partners in exchange for longer-term predictability and stability. This shift is modeled as a mid-single-digit headwind to consolidated revenue and will pressure near-term unit economics, but management presented it as a necessary step to derisk the business and align incentives for sustainable growth.

One-Time Partner Headwinds Distort Comparisons

The company cited the Rite Aid bankruptcy and lower volumes through an Integrated Savings Program partner as factors that reduced 2025 revenue by about $35 million to $40 million. These issues not only pressured last year’s results but also create a lapping effect into 2026, complicating year-over-year comparisons and amplifying the apparent deceleration in the prescription transactions line.

2026 Outlook: A Deliberate Reset Year

For 2026, GoodRx guided revenue to a range of $750 million to $780 million, implying a mid-single-digit decline from 2025 at the midpoint, and projected Adjusted EBITDA of at least $230 million, down roughly 15% from last year. Management emphasized that 2026 will be a transition year, with stepped-up investment in Pharma Direct and condition-specific subscriptions, ongoing pressure in prescription transactions revenue, a mid-single-digit drag from the unit economics reset, and monthly active consumers expected to remain roughly flat.

GoodRx’s earnings call left investors with a nuanced picture: solid 2025 execution and rapid growth in strategic businesses offset by shrinking legacy revenue and a guided step-down in 2026 profitability. Management is effectively asking shareholders to endure a reset year while it reorients the model around Pharma Direct, e-commerce, and subscriptions, positioning the stock as a potential longer-term story rather than a near-term earnings play.